OCT Guided Trans Nasal Imaging of the Small Intestine in Adults

Environmental Enteric Dysfunction Clinical Trial

Official title:

OCT Guided Trans Nasal Imaging of the Small Intestine in Adults

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT04984447
• Other study ID #: 2017P001428
• Status: Enrolling by invitation
• Phase: N/A
• Start date: September 22, 2017
• Est. completion date: December 2028

Study information

• Verified date: May 2024
• Source: Massachusetts General Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The investigators are seeking healthy adult volunteers 18-60 years and healthy pregnant women in their 2nd trimester of pregnancy for a research study to assess a new imaging device. The Tearney Laboratory at the Wellman Center for Photomedicine at Massachusetts General Hospital is developing high-resolution imaging devices that can be used to improve diagnostics in gastrointestinal diseases.

Description:

The investigators have developed a device that can image the duodenum (the first part of the small intestine). The device consists of a thin, flexible tube with a small internal camera inside of it that takes high-resolution images of the gastrointestinal tract. The device will be introduced through the nose and then advanced into the stomach and duodenum. Participant tolerability, imaging quality and the optimal imaging technique will be evaluated. The results of this study will be used as the basis for a larger study to be conducted at the Aga Khan University Hospital in Pakistan where subjects with suspected or diagnosed EED will be imaged.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 30
• Est. completion date: December 2028
• Est. primary completion date: December 2026
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• Healthy subjects

• Subjects who are in their 2nd trimester of pregnancy

• Subject must be 18-60 years of age Subject must be able to consent to the procedure.

• Subject must fast (no solid food) for at least 8 hours and have no liquids within 2 hours prior to the procedure.

Exclusion Criteria:

• Subjects with a history of upper respiratory disease or surgery

• Pregnant women with high-risk pregnancies such as history of: hyperemesis gravidarum, HIV, severe anemia or any other high-risk pregnancy conditions at the discretion of the subject's physician and the PI

• Subjects with a history of upper gastrointestinal surgery

• Pregnant women with Type 1 diabetes

• Pregnant women with Type 2 diabetes on medication and gestational diabetes requiring medication

• Pregnant women with gestational thrombocytopenia

• Subjects with upper respiratory infection at least 7 days prior to the procedure

• Subjects with any contraindications to the placement of the NJ tube including deviated septum or any other anatomical abnormalities of the nasopharynx or upper gastrointestinal region, history of trans-sphenoidal surgery, facial or cranial trauma and fractures, chronic sinusitis, esophageal strictures, varices etc.

• Subjects on medications that delay gastric emptying.

• Patients on drugs which impair clotting like anticoagulants and antiplatelet drugs, NSAIDS, history of bleeding disorders.

• Subjects using nasal steroids or any steroids for environmental allergies.

Related Conditions & MeSH terms

• Environmental Enteric Dysfunction

Intervention

Device:
• TNIB Catheter
Subjects will be asked to fast for 8 hours prior to study procedure and no liquids 2 hours prior to study procedure. Lidocaine jelly will may be used to help insert the TNIB Catheter through the Nares. Once inserted past the pharynx, imaging will begin. We will attempt to image the duodenum within 3 hours of study procedure starting.

Locations

Country	Name	City	State
United States	Massachusetts General Hospital	Boston	Massachusetts

Sponsors (2)

Lead Sponsor	Collaborator
Massachusetts General Hospital	Bill and Melinda Gates Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Ability for subject to tolerate the device	Can the subject tolerate the administration of the device with minimal discomfort?	3 hours
Primary	Ability to visualize gastrointestinal features	Can the technology successfully visualize gastrointestinal features?	6 months